Unicycive Therapeutics Joins Russell Microcap® Index
01 juil. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
25 juin 2024 07h30 HE
|
Unicycive Therapeutics, Inc.
– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS...
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
13 juin 2024 11h39 HE
|
Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...
Purespring Therapeutics presents preclinical data at the 61st ERA Congress
24 mai 2024 10h57 HE
|
Purespring Therapeutics
Purespring Therapeutics presents preclinical data at the 61st ERA Congress Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to replace defective genes or to...
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
23 mai 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
13 mai 2024 16h16 HE
|
Unicycive Therapeutics, Inc.
– On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 – – Multiple Presentations on OLC and UNI-494 at Prominent, Upcoming Medical...
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
30 avr. 2024 14h40 HE
|
Spherix Global Insights
EXTON, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent...
AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease
23 avr. 2024 06h00 HE
|
Averoa
Grenoble, France, 23rd April 2024 - Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, announces the submission of a marketing authorisation...
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
25 mars 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
18 mars 2024 07h05 HE
|
Sequel Med Tech
Sequel’s twiist™ automated insulin delivery system receives FDA 510(k) clearance. Significant advancements for people with people with Type 1 diabetes.